<DOC>
	<DOCNO>NCT00888654</DOCNO>
	<brief_summary>RATIONALE : The use diindolylmethane , substance find cruciferous vegetable , may slow growth tumor cell . PURPOSE : This phase II trial study well diindolylmethane work treat patient stage I stage II prostate cancer undergo radical prostatectomy .</brief_summary>
	<brief_title>Diindolylmethane Treating Patients With Stage I Stage II Prostate Cancer Undergoing Radical Prostatectomy</brief_title>
	<detailed_description>OBJECTIVES : Primary - To measure level diindolylmethane prostate tissue treatment oral microencapsulated diindolylmethane ( B-DIM ) patient stage I II adenocarcinoma prostate undergoing radical prostatectomy . Secondary - To measure serum biomarkers ( e.g. , total PSA , serum testosterone , diindolylmethane level ) pre- post-treatment B-DIM . - To measure tissue biomarkers ( e.g. , androgen receptor , NF-κB , PSA ) pre- post-treatment B-DIM . OUTLINE : This multicenter study . Patients receive oral microencapsulated diindolylmethane ( B-DIM ) twice daily 14-72 day absence disease progression unacceptable toxicity . Patients undergo radical prostatectomy 1 day last dose B-DIM . Patients undergo blood tissue sample collection correlative laboratory study . Blood sample analyze serum PSA , testosterone , diindolylmethane level high performance liquid chromatography tandem mass spectrometry ( LC-MS/MS ) . Tissue sample analyze diindolylmethane concentration LC-MS/MS androgen receptor , activate NF-κB ( p65 antibody ) , PSA expression IHC .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>3,3'-diindolylmethane</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm adenocarcinoma prostate Stage I II ( T1T2 , b , c ) disease Disease confine prostate clinical judgment surgeon Deemed appropriate candidate surgery clinical judgment surgeon PATIENT CHARACTERISTICS : ECOG performance status 02 ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 8.0 g/dL Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST and/or ALT ≤ 2.5 time ULN alkaline phosphatase normal OR alkaline phosphatase ≤ 4 time ULN AST and/or ALT normal Serum creatinine ≤ 2.0 mg/dL No history allergic reaction attribute compound similar chemical biological composition oral microencapsulated diindolylmethane No concurrent uncontrolled illness include , limited , follow : Ongoing active infection Symptomatic congestive hart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness social situation would limit compliance study requirement PRIOR CONCURRENT THERAPY : No prior chemotherapy , hormonal therapy , brachytherapy , cryotherapy , external beam radiotherapy , therapy prostate cancer No concurrent micronutrient supplement dietary soy product No concurrent systemic therapy cancer No concurrent p450 inducer inhibitor ( e.g. , carbamazepine , clarithromycin , fluconazole , fosphenytoin , itraconazole , ketoconazole , phenobarbital , phenytoin , rifabutin , rifampin ) No concurrent finasteride dutasteride No concurrent investigational commercial agent therapy malignancy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage II prostate cancer</keyword>
</DOC>